کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1998532 | 1065812 | 2012 | 4 صفحه PDF | دانلود رایگان |
Here we provide the first evidence that therapeutic levels of a lysosomal enzyme can bypass the blood–brain barrier following intranasal administration. α-l-iduronidase (IDUA) activity was detected throughout the brains of IDUA-deficient mice following a single intranasal treatment with concentrated Aldurazyme® (laronidase) and was also detected after intranasal treatment with an adeno-associated virus (AAV) vector expressing human IDUA. These results suggest that intranasal routes of delivery may be efficacious in the treatment of lysosomal storage disorders.
► A novel non-invasive route of delivery for lysosomal enzyme to the CNS.
► Delivery of IDUA to the brain by intranasal administration of laronidase.
► Delivery of IDUA to the brain by intranasal administration of an AAV vector.
Journal: Molecular Genetics and Metabolism - Volume 106, Issue 1, May 2012, Pages 131–134